1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center


Stan Swartz, CEO,
The MD Health Channel

"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
"At 92...I had lost my will to live"
Tips on Aging
"Dr. Reyes gave me customized health care"

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
Runtime: 50:22
Runtime: 50:22
Runtime: 10:27
Runtime: 10:27
Runtime: 5:00
Runtime: 5:00
PDF Document 850 kb

Download Free

Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
Free Windows Media Player Click

Barrow Neurological Institute

October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  
August 2018  
September 2018  
October 2018  
November 2018  
December 2018  
January 2019  
February 2019  

This page is powered by Blogger. Isn't yours?

Monday, May 22, 2017


How One Town Hopes to Cure Alzheimer's

Judy Culbertson gets lost sometimes. She might be on her way home from the grocery store or some other place she’s been dozens of times, when she suddenly finds herself on a street she doesn’t recognize.

“Then I call somebody and they tell me which way to go,” says Culbertson, 74. “It’s scary.”

Incidents like these pushed Culbertson to attend a “Meet the Memory Doctor” town hall in Columbus, GA, last month. Culbertson, who lives just across the border in Phenix City, AL, was among 184 older adults who crowded into a packed conference room to hear neurologist Jonathan Liss, MD, speak. His pitch: “Make Columbus, GA, the focal point of the world’s effort to cure Alzheimer’s disease.”

The meeting is part of a 3-year citywide initiative, The Columbus Memory Project, intended to prevent memory loss and prevent or delay the start of Alzheimer’s disease. Based at the Columbus Memory Center, the project aims to make the city the first to screen every senior citizen for memory loss and thousands more for their chance of getting Alzheimer's disease from their genes.

“If we start taking memory as seriously as we take heart disease, we will take a massive leap both in our ability to prevent Alzheimer’s disease and in our ability to treat it as soon as there’s even that earliest detection, which we now know for certain is the key to defeating this disease,” Liss said. He is funding the project with $100,000 of his own money.

Through advertising, frequent town halls, and word of mouth, the project has recruited 1,600 people so far. The goal is to test 20,000 area residents ages 65 and older for memory loss and genetic risk and offer them free yearly memory testing. Adults 55 to 75 are eligible for genetic screening tests, but memory tests typically aren’t useful until age 65.

Genes and Alzheimer's

Culbertson is among those who agreed to get a free cheek swab -- a DNA test -- to find out if she has the ApoE e4 gene. This gene variant raises the chance of having Alzheimer’s disease, but it's not a guarantee that those who have it will develop the condition. One copy of the e4 variant moderately raises the odds of having late-onset Alzheimer’s disease. Two copies raise the risk more.

“I’m certain that I want to know the results of my cheek swab,” Culbertson said. “I don’t know what the options would be, but I’m already having problems with memory, so I want to know.”

Melissa Hill, 64, of Columbus is not so sure. Watching her mother decline into dementia in the last few years has left her frightened about her own future.

“I would be more afraid of an Alzheimer’s diagnosis than anything else. If I do find out [my ApoE e4 status], I would like to know what I can do, but I have to decide if I want to know that,” she said.

People who agree to submit their DNA can decide if they want to learn their test results.

“There are many people who don’t want to know,” said Dorene Rentz, a neuropsychologist who is not involved with the Columbus Memory Project.

“What will you do if you find out?” said Rentz, co-director of the Center for Alzheimer Research at Brigham and Women’s Hospital in Boston. “Will you then restructure your life in such a way that you’re worried about yourself for the rest of your life?”

Project participants who want to know their ApoE e4 status must meet via Skype with a certified genetic counselor, who won’t yet know their results either. The counselor must verify that the participant is emotionally stable enough and understands enough to learn their genetic risk. “They have to know what it means to know this stuff,” Liss said. “We can’t just jump into it.”

Rufus Riggs, who lost his mother and a paternal aunt and uncle to Alzheimer’s disease, wants to know where he stands. At 74 years old, he hasn’t noticed any signs of memory loss, but he knows the risk might be in his genes.

“If so, I want to know. Whatever I can do to be active and self-sufficient, I will do, because if you don’t do anything, it’s like putting your head in the sand, which is not very smart in my estimation.” Riggs and his wife attended the town hall together, and both planned to get the cheek swab.

It’s not only about whether a person wants to know their status, Rentz said. “How much does the spouse want to know whether their loved one is likely to get Alzheimer’s disease? I would think it’s a family decision. These are questions that the field is still grappling with.”

Testing Your Memory

Project participants ages 65 and over can also take a memory test. Test scores on the Self-Administered Gerocognitive Examination can pick up signs of memory loss ranging from mild cognitive impairment -- which may come just before Alzheimer's dementia -- to full-fledged dementia. The aim is to give every participant what Liss calls a “memory number.” He describes it as another vital sign for seniors -- a number they should know as well as their cholesterol level and blood pressure.

The idea, he says, is to monitor memory over the years, just like cholesterol, so that doctors can step in at the first, smallest signs of memory loss. By the time a person has severe cognitive impairment, it’s usually too late to do anything to slow the disease down. “We feel pretty convinced as a research community, not just me, that the key to defeating this disease, is finding it early,” he says.

Fifty-five out of 112 people tested during the first town hall showed that they had either mild cognitive impairment or dementia. This is a far higher percentage than you would expect in the general population, Liss said. Maybe people came to the meeting because they suspect they have memory loss, or maybe the group tended to be older, he says. The project staff have not yet broken the scores down by age.

Benefits and Risks

Today, there isn’t a prescription medication that people with the ApoE e4 gene can take to prevent Alzheimer’s disease. Nor is there a pill you can take at the earliest sign of memory loss. But one day, there could be.

For people who are interested, the project connects them with clinical trials that test such treatments, among them the Generation and EARLY trials. In the Generation trial, people with two copies of ApoE e4 who have no signs or symptoms of disease can take a drug called CNP520, designed to lessen beta-amyloid plaque in the brain. Buildup of this protein in the brain advances Alzheimer’s disease. The trial aims to discover whether CNP520 can prevent it. Similarly, the EARLY trial offers an experimental drug to people who either have the ApoE e4 gene or beta-amyloid plaque in their brain with no other symptoms of disease.

In the best-case scenario, participants get personal health benefits from the project or a clinical trial while helping advance research. But taking part in the studies can be risky. “These treatments are all experimental and have risks that we don’t know about,” said Rentz.

Screening tests may bring unexpected risks and consequences, too. “One of the things about screening is that it tends to lead to subsequent testing,” said Gilbert Welch, a professor of medicine at the Dartmouth Institute for Health Policy and Clinical Research in Hanover, NH. His research focuses on how finding disease early can affect people.

“For real people, suddenly that starts to involve real anxiety and real money, which comes out-of-pocket and only adds to anxiety,” he says.

Story Source: The above story is based on materials provided by WEBMD
Note: Materials may be edited for content and length